Alteplase for the treatment of acute ischaemic stroke: a single technology appraisal

M Lloyd Jones* and M Holmes
ScHARR, University of Sheffield, Sheffield, UK

*Corresponding author

Declared competing interests of authors: none

Abstract

This paper presents a summary of the evidence review group report into the clinical effectiveness and cost-effectiveness of alteplase for the treatment of acute ischaemic stroke, in accordance with the licensed indication, based upon the evidence submission from the manufacturer to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The submitted clinical evidence included several randomised controlled trials indicating that, in highly selected patients, alteplase administered at a licensed dose within 3 hours of the onset of acute ischaemic stroke is associated with a statistically significant reduction in the risk of death or dependency at 3 months compared with placebo, despite a significantly increased risk of symptomatic intracranial haemorrhage within the first 7–10 days. Data from the National Institute of Neurological Disorders and Stroke (NINDS) trial suggest that the benefit of treatment is sustained at 6 and 12 months. However, data from observational studies suggest that few patients with acute ischaemic stroke will be eligible for alteplase therapy under the terms of the current licensing agreement. In particular, many patients will be excluded by virtue of their age, and many more by the restriction of therapy to patients in whom treatment can be initiated within 3 hours of symptom onset. The manufacturer’s submission included a state transition model evaluating the impact of treatment with alteplase within 3 hours of onset of stroke symptoms compared to standard treatment reporting that, in the base-case analysis, alteplase was both less costly and more effective than standard treatment. This increased to a maximum of approximately £4000 upon one-way sensitivity analysis of the parameters. The

HTA 06/51/01

Date of ERG submission: February 2007
TAR Centre(s): School of Health and Related Research (ScHARR)
List of authors: M Lloyd Jones and M Holmes
Contact details: Myfanwy Lloyd Jones, Senior Research Fellow, ScHARR, University of Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA, UK E-mail: m.lloydjones@sheffield.ac.uk

The research reported in this article of the journal supplement was commissioned and funded by the HTA programme on behalf of NICE as project number 06/51/01. The assessment report began editorial review in October 2008 and was accepted for publication in March 2009. See the HTA programme web site for further project information (www.hta.ac.uk). This summary of the ERG report was compiled after the Appraisal Committee’s review.

The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Department of Health.

Discussion of ERG reports is invited. Visit the HTA website correspondence forum (www.hta.ac.uk/correspond).
probabilistic sensitivity analysis presented within
the submission suggests that the probability that
alteplase has a cost-effectiveness ratio greater than
£20,000 per quality-adjusted life-year (QALY)
gained is close to 1 (0.99). The results of the
short-term model demonstrate that alteplase is
cost-effective over a 12-month period, with an
incremental cost-effectiveness ratio of £14,026
per QALY gained. This increased to a maximum
of £50,000 upon one-way sensitivity analysis of
the parameters. At 12 months, the probabilistic
sensitivity analysis presented within the submission
suggests that the probability that alteplase has a
cost-effectiveness ratio greater than £20,000 per
QALY gained is approximately 0.7. The guidance
issued by NICE in April 2007 as a result of the
STA states that alteplase is recommended for the
treatment of acute ischaemic stroke only when
used by physicians trained and experienced in the
management of acute stroke and in centres with the
required facilities.

**Introduction**

The National Institute for Health and Clinical
Excellence (NICE) is an independent organisation
within the NHS that is responsible for providing
national guidance on the treatment and care of
people using the NHS in England and Wales.
One of the responsibilities of NICE is to provide
guidance to the NHS on the use of selected new
and established health technologies, based on an
appraisal of those technologies.

NICE’s single technology appraisal (STA) process
is specifically designed for the appraisal of a single
product, device or other technology, with a single
indication, for which most of the relevant evidence
lies with one manufacturer or sponsor.\(^1\) Typically,
it is used for new pharmaceutical products close
to launch. The principal evidence for an STA is
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report
reviewing the evidence submission is submitted
by the evidence review group (ERG); an external
organisation independent of NICE. This paper
presents a summary of the ERG report for the STA
of alteplase for the treatment of acute ischaemic
stroke.\(^2\)

**Description of the underlying health problem**

‘Stroke’ is a term used to refer to the clinical
syndrome that results from the interruption of
the blood supply to an area of the brain.
Approximately 85% of all strokes occur when the
blood supply to the brain is blocked, either by a
blood clot or by narrowing of the blood vessels:
such strokes are termed ischaemic strokes.\(^3\) Most
other strokes occur when a blood vessel in or
around the brain ruptures: these are termed
haemorrhagic strokes.\(^3\)

In England, stroke is one of the top three causes
of death.\(^2\) It is also the leading cause of adult
disability;\(^4\) at least 300,000 people in England live
with moderate to severe disabilities as a result of
stroke.\(^3\)

alteplase is an enzyme that causes blood clots
to dissolve. It is therefore of potential value
in ischaemic stroke because it may enable the
restoration of the blood supply to the affected
area of the brain. However, it is also associated
with a risk of intracerebral haemorrhage.
Moreover, because it dissolves blood clots, its
use in haemorrhagic stroke is potentially fatal
or disabling. Alteplase is not licensed for use in
patients older than 80 years.

**Scope of the evidence review group report**

The principal research question relates to the
clinical effectiveness and cost-effectiveness of
alteplase for the treatment of acute ischaemic
stroke. The manufacturer’s scope restricts the
intervention to intravenous alteplase given to
adults with ischaemic stroke within 3 hours of
symptom onset, in a secondary care setting, under
the guidance of experienced stroke and neuro-
imaging specialists, and after prior exclusion of
intracranial haemorrhage. The scope restricts the
comparator to placebo or standard medical and
supportive management without thrombolysis.
This is because no thrombolytic treatment other
than alteplase is licensed in the UK for use in acute
ischaemic stroke, and other stroke treatment or
prevention therapies that function in different ways
would not be relevant comparators.

The single most clinically relevant and important
outcome measure is the proportion of patients
suffering death or dependency (reported as a score
of 3–6 inclusive on the modified Rankin scale).
This captures in one measure alteplase’s impact
on both the proportion of patients making a good
functional recovery and the proportion suffering
asymptomatic intracranial haemorrhage (SICH),
an outcome associated with death or increased
disability. Other relevant outcomes include survival;
neurological deficit; mental health (including
anxiety and depression); adverse effects of
treatment (including bleeding events); and health-related quality of life. Economic outcomes include cost per quality-adjusted life-year (QALY) gained.

Methods

The ERG report comprised a critical review of the evidence for the clinical evidence and cost-effectiveness of the technology based upon the manufacturer’s submission to NICE as part of the STA process. In addition, in an attempt to ensure that no relevant randomised controlled trials were overlooked, the ERG ran in MEDLINE both the manufacturer’s search strategy and the search strategy previously used in the Cochrane review of thrombolysis for acute stroke. This established that, while the manufacturer’s MEDLINE search strategy identified the key publication relating to each of the included trials, it did not identify the important reanalysis of the National Institute of Neurological Disorders and Stroke (NINDS) study, two supplementary analyses that the submission identified as relevant, or the Cochrane review on which the submission drew heavily.

The manufacturer’s submission also drew on evidence from a number of observational studies. It is not clear how these were identified. The submission implied that the same search strategies were used to identify both randomised controlled trials and studies investigating or evaluating service delivery or provision of technology. However, as the manufacturer’s EMBASE and MEDLINE search strategies both contained a term limiting the search to clinical trials, neither would have reliably identified observational studies. Supplementary data provided by the manufacturer stated that a systematic search was undertaken for observational studies, but did not provide a relevant search strategy and, within the time available, the ERG was not able to conduct supplementary searches to ensure that relevant observational studies were not missed. The manufacturer’s exclusion criteria arbitrarily excluded observational studies that were small (<100 patients) or added nothing to the conclusions that could be drawn from the larger studies. No indication was given as to the number of studies that were excluded for these reasons. Inclusion of those studies that were excluded because they did not contain a new message would have enabled estimation of the strength of evidence for the messages contained in the included studies.

The manufacturer did not undertake independent meta-analyses, but referred to those undertaken for the Cochrane review (which were calculated as odds ratios using the Peto fixed-effects method), and the pooled analysis of the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) A and B, European Cooperative Acute Stroke Study (ECASS) II, and NINDS 1 and 2 trials (which again used the odds ratio). The ERG therefore carried out meta-analyses to explore the effects of excluding a study (ECASS I) that used an unlicensed dose of alteplase and of presenting the results as relative risks, as required by NICE, rather than as Peto odds ratios.

The ERG had concerns about some of the methods used by the manufacturer in the cost-effectiveness modelling. This included the use of odds ratios in the model instead of relative risks, and the length of the model cycle time. The manufacturers were asked to justify the use of these methods and were requested to perform additional analyses using methods considered by the ERG to be more appropriate. In all cases the manufacturers complied with these requests. The additional analyses showed no meaningful differences in either the direction or the magnitude of the results compared with the original work.

Results

Summary of submitted clinical evidence

Evidence from randomised controlled trials indicates that, in highly selected patients, alteplase administered at a licensed dose within 3 hours of the onset of acute ischaemic stroke is associated with a statistically significant reduction in the risk of death or dependency at 3 months compared with placebo [relative risk (RR) 0.82, 95% confidence interval (CI) 0.72 to 0.93, absolute risk reduction 11%; Figure 1], despite a significantly increased risk of SICH within the first 7–10 days [RR 4.24, 95% confidence interval (CI) 1.52 to 11.83, absolute risk increase 6%]. Data from the NINDS trial, the only study which presented data relating to a time point later than 3 months from stroke onset, suggest that the benefit of treatment is sustained at 6 and 12 months.

However, data from observational studies suggest that few patients with acute ischaemic stroke will be eligible for alteplase therapy under the terms of the current licensing agreement. In particular, many patients will be excluded by virtue of their age, and many more by the restriction of therapy to patients in whom treatment can be initiated within 3 hours of symptom onset. In principle, it may be possible to increase the proportion of patients who
both reach hospital and are assessed for alteplase therapy within 3 hours, but to do so would require substantial investment in public education, and possibly also service reconfiguration. Moreover, the risk of major protocol violations in the administration of alteplase should be noted. In two comprehensive independent community-based studies, the Cleveland9 and Connecticut10 studies (of which only the former was cited in the manufacturer’s submission), such violations, most of which appeared to have been accidental,10 affected 67% of patients receiving alteplase in Connecticut and 50% in the Cleveland area.

Summary of submitted cost-effectiveness evidence

A state transition model was used to evaluate the impact of treatment with alteplase within 3 hours of onset of stroke symptoms compared to standard treatment. The time horizon for this long-term model was 40 years. In addition, a short-term (12-month follow-up) model is included. The model is based on work published as part of the Health Technology Appraisal (HTA) of thrombolytic therapy by Sandercock et al.11

The main data source for the model is a Cochrane review meta-analysis of the NINDS,12 ECASS I,13 ECASS II,14 ATLANTIS A,15 ATLANTIS B16 and Haley et al.17 studies. Outcomes from this meta-analysis are extrapolated over a time horizon of 40 years in order to assess the long-term benefits and costs of alteplase. The model takes into account the increased rate of haemorrhage seen in alteplase-treated patients.

The health states used within the model and the costs and utilities associated with each health state are considered to be appropriate for the required analysis.

The Boehringer Ingelheim model estimated that, in the base-case analysis, alteplase was both less costly and more effective than standard treatment. This increased to a maximum of approximately £4000 upon one-way sensitivity analysis of the parameters.

The probabilistic sensitivity analysis presented within the submission suggests that the probability that alteplase has a cost-effectiveness ratio greater than £20,000 per QALY gained is close to 1 (0.99).

The results of the short-term model demonstrate that alteplase is cost-effective over a 12-month period, with an incremental cost-effectiveness ratio (ICER) of £14,026 per QALY gained. This increased to a maximum of £50,000 upon one-way sensitivity analysis of the parameters.

At 12 months, the probabilistic sensitivity analysis presented within the submission suggests that the probability that alteplase has a cost-effectiveness ratio greater than £20,000 per QALY gained is approximately 0.7.

Commentary on the robustness of submitted evidence

The evidence for the clinical effectiveness of alteplase when used within the 3-hour licensed window for the treatment of acute ischaemic
stroke is not robust and, as noted in a recent Cochrane review, should be treated with extreme caution. It is based on a total of only 416 patients who received the current licensed dose of alteplase within the 3-hour time window (see Figure 1). Moreover, 312 of these patients were enrolled in one trial, the NINDS trial, in which a substantial imbalance in baseline stroke severity, a key prognostic factor, favoured alteplase. An additional analysis undertaken by the Cochrane reviewers suggested that the imbalance probably caused the effect of alteplase on death and dependency to be overestimated by around 3%. However, a subsequent independent analysis of the NINDS data considered that there was no evidence that the imbalance in the distribution of baseline NIHSS (National Institute for Health Stroke Scale) scores had either a statistically or a clinically significant effect on the trial results. The randomised trials were not stratified by any potential prognostic factor other than time to treatment, and therefore any post hoc analyses designed to explore the extent to which different groups might benefit from therapy can only be regarded as hypothesis generating. Nonetheless, it is interesting to note that a pooled analysis of data from the ATLANTIS A and B, ECASS II, and NINDS trials appeared to indicate that alteplase therapy was of significant benefit in women, but not in men (Table 1).

The model structure is appropriate and allows sensitivity analysis to be carried out easily. Given a 40-year time horizon, one-way sensitivity analysis suggests that variations in the majority of the parameters do not have a large effect upon the ICER. Alteplase dominates (i.e. costs less and is more effective than) standard treatment; potential parameter variations are unlikely to increase the ICER beyond the currently accepted threshold values. The results at 12 months, when the full lifetime costs associated with disability due to stroke and the QALY gain associated with increased survival are not captured, indicate that alteplase is still cost-effective. No weaknesses in the model structure were identified that would alter the results significantly. However, the model rests on evidence for the clinical effectiveness of alteplase administered with 3 hours of symptom onset which, as noted above, is not robust. Moreover, although the risks and benefits of alteplase are unknown beyond 12 months, the manufacturer’s health economic model has used a lifetime horizon of 40 years. In addition, the economic evaluation relies heavily on the results of the NINDS trial in which, as noted above, a substantial imbalance in baseline stroke severity favoured alteplase. Thus, the results of the cost-effectiveness analysis should be treated with extreme caution.

One important issue which is not explicitly taken into account in the economic modelling is the possible impact of trying to increase the number of patients who could be treated within the 3-hour window. This could have a significant cost impact to the NHS in terms of both the need to educate the public on the importance of early treatment and potential substantial service reconfiguration.

### Conclusions

The evidence from randomised controlled trials suggests that, in highly selected patients, alteplase administered within 3 hours of the onset of acute ischaemic stroke is associated with a statistically significant reduction in the risk of death or dependency at 3 months compared with placebo, despite the statistically significant increase in the risk of early SICH. However, this evidence should be treated with extreme caution as it is based on a total of only 416 patients who received the current licensed dose of alteplase, and 312 of these patients were included in a trial in which a substantial imbalance in baseline stroke severity, a key prognostic factor, favoured alteplase.

<table>
<thead>
<tr>
<th></th>
<th>Alteplase</th>
<th>Placebo</th>
<th>p-value (alteplase vs placebo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men</td>
<td>38.5%</td>
<td>36.7%</td>
<td>0.52</td>
</tr>
<tr>
<td>Women</td>
<td>40.5%</td>
<td>30.3%</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>p-value (men vs women)</td>
<td>0.50</td>
<td>0.03</td>
<td></td>
</tr>
</tbody>
</table>

Kent et al. did not present these data in such way as to allow the calculation of relative risks and confidence intervals.
Observational studies suggest that few patients with ischaemic stroke will be eligible for alteplase therapy under the terms of the current licensing agreement. In particular, many patients will be excluded because they are older than 80 years, and many more will be excluded because treatment cannot be initiated within 3 hours of symptom onset. Any increase in the number of patients in whom treatment can be initiated within 3 hours is likely to require substantial efforts in terms of public education and service reconfiguration.

The critical appraisal of the Boehringer Ingelheim model undertaken by the ERG suggests that alteplase can result in long-term cost savings and is more effective than standard treatment. In the short-term, when the full lifetime costs associated with disability due to stroke and the QALY gain associated with increased survival are not captured, alteplase was still shown to be cost-effective compared to standard treatment.

**Summary of NICE guidance issued as a result of the STA**

At the time of writing, the final appraisal determination document issued by NICE in April 2007 states that:

Alteplase is recommended for the treatment of acute ischaemic stroke when used by physicians trained and experienced in the management of acute stroke. It should only be administered in centres with facilities that enable it to be used in full accordance with its marketing authorisation.

**Key references**


15. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-


